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Abstract: Our study demonstrates that the intrathecal administration of bare acetalated dextran
(AcDX) microspheres can protect neurons from glutamate (GLU)-induced
excitotoxicity, and therefore, repair the injured spinal cord. The neuroprotective feature
of AcDX microspheres is achieved by sequestering GLU and calcium ions in
cerebrospinal fluid (CSF), reducing the calcium ions influx into neurons and inhibiting
the formation of ROS. Consequently, AcDX microspheres attenuate the expression of
pro-apoptotic proteins (Calpain and Bax) and enhance the expression of anti-apoptotic
protein (Bcl-2) both in vitro and in vivo. The intrathecal administration of AcDX
microspheres immediately after traumatic injury leads to histological protection in spinal
tissue and functional recovery in live animals. In summary, our work opens an exciting
perspective toward the application of neuroprotective AcDX for the treatment of severe
neurological diseases.
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Spinal cord injury (SCI) is the result of an initial mechanical disruption in the spinal cord structures 
(primary insult), followed by a secondary event that collectively injures the intact neighboring tissue.[1] 
Worldwide, an estimated 2.5 million people are living with SCI, with more than 130 thousand new 
injuries reported annually.[2] Traumatic SCI is a debilitating injury that have a life-long impact on the 
injured person. The economic cost of SCI is estimated to be approximately 9.7 billion dollars annually 
in the United States.[3] Despite its significant societal and economic impacts, few clinical treatments 
exist for traumatic SCI, and they only have limited therapeutic efficacy.[4] Therefore, new therapeutic 
strategies with improved therapeutic efficacy have been actively pursued.[5] 
One of the promising approaches to treat traumatic SCI is using biomaterials. Several biodegradable 
polymers have been illustrated to support or promote axon regeneration in central nervous system. For 
example, the local administration of hydrogel composing of poloxamers (nonionic amphiphilic 
triblock copolymers) has been shown to slightly improve the functional motor recovery of injured 
spinal cord.[6] The self-assembled poly(ethylene glycol)−poly(D,L-lactic acid) block copolymer 
micelles repair the injured axonal membranes and reduce the calcium influx into axons, resulting in an 
improvement of locomotor function after traumatic SCI in adult rats.[7] Functional restoration of 
injured spinal cord has also been observed through the intravenously administration of ferulic acid 
modified glycol chitosan nanoparticles at 2 h post-injury.[8] Moreover, poly(lactic-co-glycolic acid),[9] 
poly(caprolactone fumarate)[10] and oligo[(polyethylene glycol) fumarate][11] have previously been 
shown to benefit the neuron repair.[12] 
Recently, a biodegradable water-insoluble polymer ‘acetalated-dextran’ (AcDX) was synthesized 
by modifying hydroxyl groups of water-soluble dextran with 2-methoxypropene.[13] Because of its 
high solubility in organic solvents, AcDX and its derivatives have been formulated into micro- and 
nano-particles for biomedical applications, such as immunotherapy[14] and myocardial infarction 
treatment.[15] The immunogenicity of subunit vaccines could be enhanced by encapsulating a protein 
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hepatocyte growth factor fragment were employed for the treatment of myocardial infarction.[15] The 
cardioprotective efficacy of payload was optimal when delivered over 3 days post-intramyocardial 
injection, yielding the largest arterioles and the fewest apoptotic cardiomyocytes bordering the 
infarct.[15a] 
After SCI, glutamate (GLU) floods out of injured spinal neurons, axons, and astrocytes, 
overexciting neighboring neurons.[16] The overexcited cells let in waves of calcium ions, which can 
trigger a series of destructive events, including production of highly reactive free radicals. These 
radicals can attack membranes and other cell organelles, and result in the neuronal death. These 
processes inevitably aggravate the injury of spinal cord. Hence, capturing GLU at the acute phase of 
injury may offer new treatment modalities for SCI therapy. In this study, we found out that the polymer 
AcDX itself can protect the injured spinal cord by reducing the level of GLU in cerebrospinal fluid 
(CSF) within hours after injection, and therefore, inhibit the GLU-induced excitotoxicity. Specifically, 
the intrathecally injected AcDX microspheres reduced the traumatic lesion volume, inhibited 
inflammatory response, protected the spinal cord neurons, and ultimately showed the improved 
locomotor function following traumatic SCI. 
The synthesis approach of AcDX is shown in Figure 1a.[13] In the presence of an acid catalyst (p-
toluenesulfonate), the modification of vicinal diols with 2-methoxypropene efficiently transformed the 
water soluble dextran into water insoluble AcDX.[14] Based on the 1H nuclear magnetic resonance 
(NMR; Figure 1b) spectrum of AcDX, the calculated conjugation ratio was approximately 80.4%, 
corresponding to 48 out of 60 glucose units in a dextran (MW 10,000 g/mol) modified by 2-
methoxypropene. Fourier transform infrared (FTIR; Figure 1c) spectra showed a clear intensity 
decrease of the O-H stretch at 3325 cm-1, which can be ascribed to the reaction of vicinal diols with 2-
methoxypropene. 
Microfluidic technology provides an easy-to-use approach for the preparation of monodisperse 
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focusing device (Figure 1d).[18] The device was composed of two types of capillaries for which the 
outer diameter (about 1.0 mm) of the cylindrical tapered capillary fitted the inner dimension (about 1.1 
mm) of the outer capillary. The inner oil fluid was an AcDX ethyl acetate solution (20 mg/mL) and 
the outer aqueous fluid contained amphiphilic Poloxamer 407 (10 mg/mL). The oil and aqueous fluids 
were simultaneously pumped into the microfluidic device in the opposite directions. This flow-
focusing geometry forced the inner oil fluid to breakdown, forming single O/W emulsion drops at the 
orifice of the inner capillary. All the collected droplets were solidified through the diffusion of ethyl 
acetate to the external aqueous phase. As shown in the scanning electron microscope (SEM) image 
(Figure 1e-i), the obtained AcDX microspheres are all spherical. Toward the fluorescein 
isothiocyanate (FITC)-loaded AcDX microspheres, the fluorescence intensity distribution within 
microspheres was uniform (Figure 1e-ii), indicating a solid structure of the obtained microspheres.[19] 
We can see from Figure 1e-iii, the average particle size of AcDX microspheres was approximately 
7.2 µm with a narrow size distribution (polydispersity index = 11.1%, defined as the ratio between the 
standard deviation and the mean diameter of particles multiplied by 100%). 
To monitor the degradation behavior of AcDX microspheres, the FITC-labelled AcDX was 
synthesized by modifying the vicinal diols of FITC-labelled dextran with 2-methoxypropene. At pH 
7.4, AcDX decomposed slowly through hydrolyzation of the acetals, regenerating the water-soluble 
FITC-dextran over a period of 50 days (Figure 1f).[15b] This degradation of AcDX microspheres is 
further reflected in the release profile of a model payload, FITC (Figure 1f). The release of FITC from 
AcDX microspheres was faster than that of FITC-dextran, which was only observed after 8 days of 
incubation. These two release profiles suggest that the payload only diffused out when the 
microspheres degraded, as opposed to passive diffusion through the intact microspheres. To 
corroborate these results, the degradation of AcDX microspheres was visualized using SEM. The 
morphology of the AcDX microspheres at day 1, 7, and 28 is shown in Figure 1g. The increased 
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at pH 7.4, most of the polymer matrix for AcDX microspheres was degraded. These SEM images 
correlate well with the observed FITC and FITC-dextran release profiles. 
We evaluated the cytocompatibility (activity of dehydrogenases) of AcDX microspheres with 
primary neurons (Figure 1h). No obvious cytotoxicity was observed for AcDX microspheres within 
the tested concentration range (0.1−4.0 mg/mL) and the selected incubation time (6−96 h). 
Interestingly, enhanced neuron activity was observed after incubating with AcDX microspheres for 24, 
48 and 72 h. After 24 h incubation, notable neuron viability enhancement was only observed for the 
highest concentration of AcDX microspheres (4.0 mg/mL). When the incubation time was extended 
to 48 h, remarkable cell viability increase was observed for AcDX microspheres with a concentration 
as low as 0.2 mg/mL. The cell viability enhancement effect for AcDX microspheres disappeared after 
increasing the incubation time to 96 h, which could be ascribed to the accumulation of by-products of 
cellular metabolism inside the medium. The cytocompatibility test suggests the neuroprotective effect 







































































Figure 1. Preparation and characterization of AcDX microspheres and their neuronal 
compatibility. (a-c) Single-step synthesis of AcDX (a), and its NMR (b) and FTIR (c) spectra. (d) A 
schematic diagram of AcDX microspheres prepared by droplet microfluidics. (e) SEM (i) and confocal 
fluorescence microscopy (ii) images of the obtained AcDX microspheres, and their size distribution 
(iii). (f) Dissolution of FITC-dextran and FITC from AcDX microspheres in 1 × phosphate-buffered 
saline (1 × PBS, pH 7.4) at 37 °C (n = 3). (g) SEM images of AcDX microspheres after 1, 7 and 28 
days of incubation in PBS (pH 7.4) at 37 °C. (h) The effect of AcDX microspheres (0.1-4.0 mg/mL) 
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microspheres were compared with that of the PBS group. Data present as mean ± s.d.; the levels of 
significance were set at probabilities of *P < 0.05 and **P < 0.01. 
 
To verify the neuroprotective effect of AcDX microspheres, we performed a functional motor 
assessment and histological injury study in Sprague-Dawley rats undergoing a weight-drop injury of 
the thoracic spinal cord (T10; Figure 2a). Regarding all the in vivo test, AcDX microspheres (60 µg/µL, 
10 µL in total) were intrathecally administrated within 5 min post-injury. Because the cerebrospinal 
fluid volume in rat brain is approximately 580 μL,[20] the theoretical total volume would be 
approximately 590 μL after the administration of AcDX microspheres. Therefore, the final AcDX 
concentration (600 µg in 590 µL) achieved about 1 mg/mL, which was proved to be effective in neuron 
viability enhancement (Figure 1h). The vehicle PBS served as the control (SCI group). The 
degradation rate of AcDX is primarily controlled by the pH value of the incubation medium.[21] After 
intrathecally administration, the AcDX microspheres were dispersed in CSF. In general, CSF is clear, 
colorless, nearly acellular, and has a low protein concentration.[22] Since the component, especially the 
pH value, of CSF is similar to the in vitro incubation medium, the in vivo degradation rate of AcDX is 
also expected to be close to that observed in vitro. Instead of breaking into smaller pieces, AcDX 
microspheres presented an “outside-in” pattern of degradation (Figure 1g). Their degradation pattern 
indicates that AcDX microspheres would remain inside the CSF before complete degradation. 
After traumatic SCI, the motor behavior was assessed by the 21-point Basso, Beattie, and Bresnahan 
(BBB) locomotor rating scale in open-field (Figure 2b). The complete hindlimb paralysis (BBB score 
= 0) was observed for both SCI and AcDX groups at day 1 post-injury. At day 7 post-injury, the AcDX 
group showed extensive movement of two joints (BBB score = 3.0 ± 0.8), which is significantly (P = 
0.040) higher than the locomotor performance of SCI group (BBB score = 1.8 ± 0.5) with the extensive 
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maintained over the remainder of the motor assessment study. At day 28 post-injury, the plantar 
support of the paw with weight bearing only in the support stage was observed for the AcDX group 
with a score of 8.5 ± 1.3 on the BBB scale, whereas non-treated rats were approximately 2 points lower 
(P < 0.05). Overall, AcDX significantly improved the recovery of hindlimb motor function. In terms 
of the BBB score for the SCI group, it increased from 0 at day 1 post-injury to 6.5 ± 0.6 at day 28 after 
SCI, indicating a certain degree of spontaneous motor function recovery. This spontaneous locomotor 
function recovery was also included in the result of the AcDX group. 
As shown by the gross morphology of the injured spinal cords, the traumatic lesion area (brown 
colored region) on the spinal cord was visible (Figure 2c). After treatment with AcDX microspheres, 
the lesion area was notably smaller than that of the SCI only group. A prominent pathological feature 
of SCI is the development of a fluid-filled cystic cavity that is bordered by reactive astrocytes.[23] The 
traumatic lesion cavity was identified by loss of cells using Nissl staining to study whether AcDX 
microspheres could reduce the lesion volume. Four weeks after injury, dramatic tissue loss on the 
injured spinal cord was observed (Figure 2c). The administration of AcDX microspheres caused a 
reduction in post-traumatic spinal cord tissue loss. Lesion volume was assessed by the Nissl-stained 
spinal cord sections, which sampled serially in the longitudinal plane with an interval of about 200 µm 
for each layer. As demonstrated in Figure 2c, the administration of AcDX microspheres significantly 
decreased (P = 0.002) the lesion volume (2.9 ± 0.9 mm3) compared to the SCI control group (8.6 ± 1.1 
mm3). 
To further understand the anatomical basis of the observed locomotor recovery, we examined the 
density or status of astrocytes, microglia, neurons, and axons. These cells play crucial roles in the 
spinal cord damage and repair. The cellular hypertrophy and increases in glial fibrillary acidic protein 
(GFAP) are hallmarks of astrocyte reactivity after SCI.[24] The injured spinal cord is also featured with 
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The reactive astrocytes and microglia were visualized using GFAP and CD68 immunofluorescence 
antibodies, respectively. 
Regarding the non-treatment (SCI) group, the region in proximity to the lesion area was 
characterized by hypertrophic astrocytes with multiple GFAP+ processes for both day 1 (Figures 2d 
and 2f) and 28 (Figures S1 and S2) post-injury, matching the appearance of SCI-associated local 
astrogliosis.[26] The GFAP immunoreactivity near the injury site was higher than that located further 
(> 10 mm) from the traumatic lesion area (Figure 2h). Specifically, we observed 29.4 ± 9.9% and 36.0 
± 17.8% GFAP intensity increase at 1 and 28 days post-injury, respectively, adjacent to the lesion area 
for SCI group. In the AcDX group, peritraumatic astrocytes were morphologically indistinguishable 
from astrocytes located distal to the injury site for both day 1 (Figures 2e and g) and 28 (Figure S3 
and S4) post-injury. At day 1 post-injury, the GFAP intensity of peritraumatic astrocytes was 15.0 ± 
2.7% higher than that located further from the traumatic lesion area. This effect was continuous, 
because the peritraumatic GFAP intensity was only 8.1 ± 6.7% higher than that located further from 
the traumatic lesion area at day 28 post-injury. Hence, AcDX treatment significantly (P < 0.05, for 
both day 1 and 28 post-injury) and persistently inhibited the astrocytic response, as well as reduced 
the severity of initial reactive gliosis after SCI. 
To evaluate the effect of AcDX treatment on microglial activation following SCI, we also quantified 
the number of activated microglial cells adjacent to the injury site and in the traumatic lesion area by 
immunodetection of CD68+ microglia (Figures 2d, 2e, S1 and S3). At both day 1 and 28 post-injury, 
we did not observe any notable difference (Figure S5) on the number of CD68+ cells in the 
peritraumatic area between the SCI only and AcDX groups. In contrast, a significant reduction in the 
number of CD68+ microglia in the traumatic lesion area was observed with AcDX treatment compared 
to rats injected with only PBS at both day 1 (P = 0.004) and 28 (P < 0.001) post-injury (Figure 2i). In 
the lesion area, the density of microglia was 931 ± 75 per square millimeter at day 1 post-injury. After 
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square millimeter. Regarding the AcDX group, the CD68+ microglia density only slightly increased 
from 727 ± 51 to 840 ± 219 per square millimeter within 28 days. At day 28 post-injury, a reduction 
in the number of CD68+ microglia by about 65% in the traumatic lesion area was observed with AcDX 
treatment (P < 0.001) compared to rats injected with only PBS. Besides astrocytic response inhibition, 
AcDX efficiently restrained the inflammatory response associated to the microglia activation.[27] 
Neurofilaments are cell type specific proteins in central nerve system, and qualified as potential 
surrogate markers of damage to neuron and axon.[28] The immunostaining analysis of 200 kDa subunit 
of neurofilament (NF200), which contributes to anomalous electrophoretic mobility, has been 
employed to evaluate the neuron and axon damage.[29] In the control (SCI) group (Figures 2f and S2), 
the NF200 immunoreactivity near the injury site was lower, 32.3 ± 1.7% and 29.8 ± 16.2% decrease 
at day 1 and 28 post-injury, than that located distant from the traumatic lesion area (Figure 2j). 
Regarding the AcDX group, the NF200 intensity of peritraumatic area was 19.2 ± 1.9% lower than 
that located further from the traumatic lesion area at day 1 post-injury (Figures 2g and 2j). When the 
time extended to 28 days post-injury, the NF200 intensity of peritraumatic area was only 3.9 ± 5.5% 
lower than that located further from the traumatic lesion area for the AcDX group (Figures S4 and 2j). 
In comparison with the SCI only group, a significant increase (P < 0.05 for both 1 and 28 days post-
injury) in NF200 labeling adjacent to the injury site was observed for AcDX treated group, suggesting 
the continuous neuronal protection effect of AcDX microspheres. 
Western blot analysis was used to further validate the immunofluorescence analysis (Figure 2k). A 
semi-quantitative comparison of Western blot images showed that the GFAP expression in the AcDX 
group was significantly (P = 0.048) reduced as compared to the SCI only group (Figure 2l). Besides 
GFAP, the AcDX treatment also significantly (P = 0.014) reduced the CD68 expression (activation of 
microglia) at day 1 post-injury. A comparison of the NF200 expression demonstrated that AcDX 


































































                 Submitted to  
12 
results is highly consistent with the immunohistochemical studies, suggesting that AcDX can inhibit 
the reactivity of injury-related proteins and protect the injured neurons. 
These immunohistochemistry results collectively demonstrate that AcDX microspheres not only 
suppressed the astrogliosis and inflammation, but also protected neurons, making AcDX a promising 
biomaterial for SCI treatment. The neuroprotective effect in the spinal cord tissue contributed to the 
rapid recovery of walking motion as early as 1 week after administration. The histological data 
corroborated the functional recovery results, showing that AcDX microspheres can enhance the 
recovery of injured spinal cord. However, the mechanism of neuronal protection by AcDX 
microsphere is unclear. In the following content, we further studied the possible mechanism for the 
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Figure 2. AcDX microspheres protect the traumatically injured spinal cord. (a) Schematic 
diagram of experimental design. AcDX microspheres were intrathecally injected within 5 min after 
weight drop at the T10 level. (b) The rats were functionally graded up to 28 days post-injury using the 
BBB grading scale (n = 5 animals per group). (c) Spinal cord at day 28 post-injury: (i) gross 
morphology, (ii) representative Nissl stained sagittal sections, and (iii) the lesion volumes (n = 3 


































































                 Submitted to  
14 
and CD68 (in red) in the spinal cord tissues of SCI (d) and AcDX (e) groups at day 1 post-injury. The 
boundary of cavity is indicated by the dashed lines. Right two columns are the enlarged images 
corresponding to the distant (> 10 mm) field to the lesion (upper row), and the lesion area (bottom 
row). The nuclei of all cells were stained with DAPI (in blue). (f and g) Representative 
immunohistochemical staining images of GFAP (in green) and NF200 (in red) in the injured spinal 
cord tissues of SCI (f) and AcDX (g) groups at day 1 post-injury. The dashed lines indicate the 
boundary of cavity. (h-j) Semi-quantification of GFAP intensity increase (h; n ≥ 5 animals per group), 
the number of CD68+ microglia in the traumatic lesion area (i; n ≥ 4 animals per group), and NF200 
intensity decrease (j; n ≥ 4 animals per group). (k) Representative Western blots of NF200, CD68 and 
GFAP in lesion extracts at day 1 post-trauma. (l) Semi-quantification of relative expression level of 
NF200, CD68 and GFAP, normalized to GAPDH (n = 3 animals per group). Data present as mean ± 
s.d.; the levels of significance were set at probabilities of *P < 0.05, **P < 0.01, and ***P < 0.001. 
 
Excitotoxicity is one of the most important pathological and neurochemical changes after SCI. 
Specifically, neurons are under the excessive stimulation by neurotransmitter GLU;[30] the high GLU 
concentration around the synaptic cleft induces the neuronal cell death. Neuron apoptosis contributes 
to the neuronal cell death and to the neurological dysfunction, induced by traumatic insults to the rat 
spinal cord.[31] We studied the neuronal apoptosis by propidium iodide (PI)/Hoechst 33342 (HC) 
staining (Figure 3a). The high intensity of PI indicates the cell death. HC staining was performed to 
visualize the nuclear morphology of neurons and to distinguish those apoptotic ones. The control 
neurons exhibited uniformly dispersed chromatin and intact cell membrane (PI-negative). The high 
magnification of neurons for each group is shown in Figure S6. After the administration of GLU, 
neurons exhibited typical characteristics of apoptosis, such as the condensation of chromatin, the 


































































                 Submitted to  
15 
effect of AcDX microspheres on the GLU-induced excitotoxicity model. Three concentrations of 
AcDX microspheres, 0.25 mg/mL (AcDXL), 1.0 mg/mL (AcDXM) and 4.0 mg/mL (AcDXH), were 
selected for the following in vitro tests. Independent on the AcDX concentrations tested, the number 
of neurons with nuclear condensation and fragmentation decreased after AcDX microsphere treatment. 
We further investigated the protection mode of AcDX microspheres by staining primary neurons 
with paired FITC-labelled annexin V (FAV; in green) and PI (in red), and then examined it by flow 
cytometry (Figure 3b). In terms of early apoptotic cells, there was a prolonged maintenance of 
membrane integrity and an externalization of phosphatidylserine to which the FAV could specifically 
bind. Live cells were negative for both stains, whereas early apoptotic cells were characterized by a 
high FAV signal in the absence of PI staining. The viability of neurons decreased to about 50% (Figure 
3c) after GLU-induced excitotoxicity, about one third of neurons had lost membrane integrity (PI-
positive; Figure 3d), and approximately 13% neurons were at the early apoptotic stage (FAV-positive 
and PI-negative; Figure 3e). Under the protection of AcDX microspheres, the viability of neurons was 
significantly improved (P < 0.01) for all three concentrations tested. As expected, the fraction of PI- 
and FAV-positive neurons significantly (P < 0.01) decreased when neurons were incubated with 
AcDX microspheres. The strongest protection effect was observed for the AcDXM group. The flow 
cytometry measurements were consistent with the fluorescence image analysis; both results indicated 
that AcDX microspheres can protect primary neurons from GLU-induced excitotoxicity. 
Next, we analyzed the expression level of pro-apoptotic proteins (Calpain and Bax), anti-apoptotic 
protein (Bcl-2), and the apoptotic symbol caspases enzymes in primary neurons to preliminarily 
understand the mechanism of anti-apoptosis effect of AcDX microspheres (Figure 3f).[32] Among the 
caspases discovered, caspase-3 is an executioner of apoptosis, cleaving several essential downstream 
substrates.[33] Moreover, the activation of caspase-9, an important initiator of apoptosis, has been 
implicated in SCI.[34] The semi-quantitative analysis of Western blot images is presented in Figure 3g. 
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(P < 0.001), Caspase-9 (P = 0.011) and Caspase-3 (P = 0.003), and Bax (P = 0.004) were observed in 
primary neurons, when compared to the PBS group. In contrast, the expression level of Bcl-2 notably 
decreased (P < 0.001) when GLU was added. After the administration of AcDX microspheres, the 
Western blot analyses revealed lower levels of Calpain and Caspase-9 and Caspase-3 than those of 
GLU group, whereas the expression of Bcl-2 improved. In terms of Bax, no significant difference was 
observed for the AcDXL and AcDXM groups when compared to the GLU group. The expression level 
of Bax for AcDXH was even significantly (P = 0.002) higher than that from the GLU group. The 
neuronal protection effect of AcDX microspheres can attributed to the attenuation of pro-apoptotic 
proteins (Calpain, Caspase-9 and Caspase-3) and the enhanced expression of anti-apoptotic protein 
(Bcl-2). Furthermore, the ratio of Bcl-2 to Bax is known as a key determinant of neuronal commitment 
to apoptosis.[35] Bcl-2/Bax increased for AcDX microspheres compared with GLU group, indicating 
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Figure 3. AcDX microspheres alleviate the GLU-induced neuronal apoptosis in vitro. For in vitro 
tests, the neurons were firstly incubated with microspheres for 15 min, followed by the administration 
of GLU (100 μM) for all the groups, except for the PBS one. (a) Representative fluorescence images 
of propidium iodide (PI, in red; marker of dead cells) and Hoechst 33342 (HC, in blue; nuclear marker 
for both survival and apoptotic cells) stained neurons incubated with AcDX microspheres after GLU-
induced excitotoxicity. (b) Examples of scatter plots for neurons incubated with AcDX microspheres 
after GLU-induced excitotoxicity by PI/FAV double labeling. (c−e) Quantitative results of live (c), 
and PI- (d) and FAV-positive (e) neurons with and without the treatment by AcDX microspheres (n = 
3). (f) Representative Western blot analysis of apoptosis indicated proteins in neurons incubated with 
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level of apoptosis indicated proteins in primary neurons, normalized to GAPDH (n = 3). The AcDX 
microspheres were compared with the groups of PBS (*) and GLU (#). Data present as mean ± s.d.; the 
levels of significance were set at probabilities of *, #P < 0.05, **, ##P < 0.01, and ***, ###P < 0.001. 
 
We assessed the extent of cell apoptosis in the peritraumatic zone of spinal cord by the terminal 
deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay. The selected TUENL 
assay time point was 1 day post-injury, when a burst of neuronal and glial apoptosis in gray and white 
matter at the lesion site was observed.[31] The sagittal sections of the spinal cords treated with PBS and 
AcDX microspheres are presented in Figure 4a. High magnification of sagittal sections showed a clear 
cellular alteration of typical apoptosis, green colored and indicated by white arrows (Figure S7). On 
day 1 post-injury, the numbers of TUNEL-positive (apoptotic) cells for AcDX group was dramatically 
smaller (P = 0.006) than those treated with PBS (Figure 4b). The in vivo TUNEL assay confirmed 
that AcDX microspheres can effectively inhibit the cell apoptosis in the injured spinal cord, and these 
results are consistent with the in vitro tests. 
The expression of apoptosis associated markers in the traumatic injured spinal cord was also 
evaluated by Western blot analysis (Figure 4c). The semi-quantitative comparison of Western blot 
images is shown in Figure 4d. The local delivery of AcDX microspheres prominently improved Bcl-
2 (P = 0.022) expression and significantly reduced the expression level of Calpain (P < 0.001), 
Caspase-9 (P < 0.001), Caspase-3 (P = 0.012) and Bax (P = 0.002), as compared to the SCI only group. 
AcDX microspheres attenuated the pro-apoptotic proteins (Calpain, Caspase-9 and -3, and Bax) 
expression, and enhanced the expression of anti-apoptotic protein (Bcl-2), which corroborates the in 
vitro tests (Figures 3f and 3g). In comparison to the SCI group, the higher Bcl-2/Bax ratio for the 
AcDX group indicates that the mitochondria-mediated cell death pathway in injured spinal cord can 
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Figure 4. AcDX microspheres protect the injured neurons from apoptosis in vivo. (a) 
Representative images of TUNEL-positive apoptotic cells (in green) in sagittal spinal cord sections at 
day 1 post-trauma. The nuclei of all cells were stained with DAPI (in blue). (b) Comparison of the 
number of TUNEL-positive cells with and without AcDX microspheres treatment (n = 5 animals per 
group). (c) Representative Western blots of apoptosis indicated proteins in lesion extracts at day 1 
post-trauma. (d) Semi-quantification of relative expression level of apoptosis indicated proteins, 
normalized to GAPDH. In terms of in vivo tests, the vehicle PBS served as the control (SCI group; n 
= 3 animals per group). Data present as mean ± s.d.; the levels of significance were set at probabilities 
of *P < 0.05, **P < 0.01, and ***P < 0.01. 
 
In general, the pathologically high level of GLU can cause excitotoxicity by sustained calcium ion 
influx through GLU receptor channels, which is a common pathway of neuronal apoptosis.[36] We 
employed a calcium indicator, Fluo-4 AM ester, to monitor the intracellular calcium transients before 
and after the AcDX microsphere treatment.[37] Calcium influx by microscopy live imaging was 
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change of Fluo-4 intensity in comparison to F0. The time course of the Fluo-4 signals (∆F/F0) as a 
function of time has been presented in Figure 5a. The GLU stimulation increased the peak intensity 
of Fluo-4 by approximately 5-fold, and peaked after approximately 2 min GLU stimulation. The 
incubation with ACDX microspheres before GLU stimulation effectively reduced the peak intensity 
of Fluo-4 for neurons. Specifically, the intracellular peak level of Fluo-4 reduced by approximately 
30% (P = 0.041), 41% (P = 0.001) and 45% (P < 0.001) for AcDXL, AcDXM and AcDXH groups, 
respectively, in comparison with the GLU group (Figure 5b). After 5 min GLU stimulation, the Fluo-
4 intensity difference was only observed between GLU and AcDXM (P = 0.019). Figure 5c shows the 
representative Fluo-4 fluorescence images of GLU-stimulated neurons incubated with different 
concentrations of AcDX microspheres. Overall, the neuronal protection effect of AcDX microspheres 
could be ascribed to the reduced calcium influx into neurons, which has also been observed for the 
poly(ethylene glycol)−poly(D,L-lactic acid) block copolymer.[7] 
The high calcium ion loads increase the risk for mitochondrial damage, triggering the mitochondrial 
production of reactive oxygen species (ROS).[38] Hence, we monitored the intracellular ROS level to 
further corroborate the neuronal protection effect of AcDX microspheres.[39] The cell-permeant 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA) was used as an indicator to detect the intracellular 
level of ROS in injured neurons. Oxidation of H2DCFDA, forming highly fluorescent 2',7'-
dichlorofluorescein (DCF), as determined using confocal microscopy was barely detectable in 
uninjured neurons (Figure 5d). The intensity of DCF fluorescence in GLU incubated neurons was 
markedly increased. Meanwhile, the administration of AcDX microspheres reduced the level of DCF 
fluorescence. The intensity changes of intracellular DCF fluorescence in different groups were 
confirmed by flow cytometry analysis (Figures 5e and 5f). Based on the MFI values, only the 
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Figure 5. AcDX microspheres reduce the GLU-induced calcium ion influx and production of 
reactive oxygen species. (a) The time course of the Fluo-4 signals (∆F/F0) as a function of time, with 
F0 being the baseline Fluo-4 fluorescence and ∆F the change of Fluo-4 fluorescence in comparison to 
F0. (b) Quantification of regions of interest demonstrating the effect of AcDX microspheres on 
reducing the fluorescence over time in response to GLU (n = 11). (c) Representative calcium images 
of neurons incubated with AcDX microspheres before (0 min) and after (2 min) GLU stimulation. (d-
f) Representative ROS imaging (d), flow cytometry histograms (e), and the corresponding MFI (f; n = 
3) of injured neurons incubated with AcDX microspheres. The MFI values were normalized to that of 
the PBS group. Data present as mean ± s.d.; the groups treated with AcDX microspheres were 
compared with the GLU group (*); the levels of significance were set at probabilities of *P < 0.05, **P 
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Lohmann et al.[40] synthesized glycosaminoglycan-based hydrogels, which can capture 
inflammatory chemokines to accelerate the wound healing. Inspiring by this inflammatory chemokine 
capture, we hypothesize that AcDX microspheres can alleviate the GLU-induced excitotoxicity 
through the physical adsorption of GLU. To verify this hypothesis, we evaluated the adsorption 
kinetics of GLU to AcDX microspheres, which was determined by incubation with 50 µM of GLU in 
artificial CSF (aCSF) As illustrated in Figure 6a, the more AcDX microsphere we added, the more 
GLU was adsorbed. For example, the adsorption of GLU up to about 6% was achieved, when the 
concentration of AcDX microspheres was 1 mg/mL. Moreover, the adsorption capacity of AcDXM 
and AcDXH for GLU was analyzed by incubating with a variety concentration of GLU in aCSF (25, 
50 and 100 µM) for 30 min (Figure 6b). A linear correlation of the amounts of deployed and adsorbed 
GLU was found for both AcDXM and AcDXH. By increasing the GLU concentration from 25 to 100 
µM, the percentage of GLU sequestered by AcDX microspheres decreased from 8% to 4% for AcDXM, 
and reduced from 22% to 10% for AcDXH. 
We further verified the GLU capture capability of AcDX microspheres in vivo (Figure 6c). Detailed 
CSF sampling (100-150 μL) has been illustrated in Video S1. The GLU content in CSF was analyzed 
by an ultra-performance liquid chromatography and tandem mass spectrometry; a representative 
chromatogram of GLU in the CSF sample from the SCI only group at day 2 post-injury has been 
presented in Figure S8. Before injury, the GLU concentration in CSF is approximately 4 µM (t = day 
0). For both SCI and AcDX groups, the GLU concentration in CSF continually increased until day 2 
post-injury, and then decreased to a level (approximately 2 and 1 µM for SCI and AcDX, respectively) 
even lower than the normal GLU concentration (4 µM). Until day 4 post-injury, the GLU concentration 
for AcDX group was always significantly lower than that for the SCI only group. Specifically, after 
the administration of AcDX microspheres, the GLU concentration decreased from approximately 18 
to 8 µM (P < 0.05) at 8 h post-injury, from approximately 77 to 58 µM (P < 0.001) at day 2 post-injury, 
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under the curve (AUC) of GLU concentrations in CSF (d). The AUC of GLU for the group treated by 
AcDX microspheres was also significantly (P < 0.01) lower than that of the SCI only group. Based on 
both in vitro and in vivo GLU adsorption results, we can conclude that our AcDX microspheres can 
protect neurons from excitotoxicity by sequestering the GLU in CSF. 
The overload of calcium ions is one of the most important features for the GLU-induced 
excitotoxicity, hence we also evaluated the adsorption capability of AcDX microspheres toward 
calcium ions. Surprisingly, the AcDX microspheres can also scavenge the calcium ions in aCSF 
(Figure 6e). This calcium ion scavenging capability of AcDXM and AcDXH was also confirmed by 
the relation between the deployed and adsorbed calcium ions (Figure 6f). Like the sequestering effect 
toward GLU in CSF, the administrated AcDX microspheres also reduced the intensity of the calcium 
ions in CSF (Figure 6g). In comparison to the SCI group, significantly lower calcium ion 
concentrations were observed at 8 h (P < 0.05), and day 1 (P < 0.01), 2 (P < 0.001) and 4 (P < 0.001) 
post-injury; the AUC of calcium ions for the group treated by AcDX microspheres was also 
significantly reduced (P < 0.001; Figure 6h). Therefore, the neuronal protection effect of AcDX 
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Figure 6. AcDX microspheres alleviate GLU-induced excitotoxicity by sequestering GLU and 
calcium ions. (a) The adsorption of GLU (50 µM) by AcDX microspheres in aCSF in terms of the 
microsphere concentrations (n = 6). (b) The impact of GLU concentrations on the adsorption of GLU 
by AcDX microspheres in aCSF (n = 6). (c and d) The effect of AcDX microspheres on the 
concentrations of GLU in the CSF as a function of time (c; n ≥ 3 animals per time point) and the 
corresponding area under curve (d; n = 3). (e) The adsorption of calcium ions (0.5 mM) by AcDX 
microspheres in aCSF in terms of the microsphere concentrations (n = 6). (f) The impact of calcium 
ion concentrations on the adsorption of calcium ions by AcDX microspheres in aCSF (n = 6). (g and 
h) The effect of AcDX microspheres on the concentrations of calcium ions in the CSF as a function of 
time (g; n ≥ 3 animals per time point) and the corresponding area under curve (h; n = 3). Data present 
as mean ± s.d.; the groups treated with AcDX microspheres were compared with the SCI only group 
(*); the levels of significance were set at probabilities of *P < 0.05, **P < 0.01 and ***P < 0.001. 
 
GLU and calcium ions play a key role in excitotoxicity, which leads to neuronal cell apoptosis.[41] 
AcDX microspheres show the capability of buffering out excess GLU and calcium ions. Benefiting 
from the fast sequestering of GLU and calcium ions by AcDX microsphere, significantly lower level 
of GLU and calcium ions in CSF has been achieved at the first evaluation time point (8 h post-injury). 
By reducing the magnitude of the initial increase of extracellular GLU and calcium ions during the 
acute (2-48 h post-injury) and subacute (2-14 days post-injury) phases of SCI,[42] AcDX microspheres 
successfully attenuate the degree of excitotoxic secondary neuron damage. Like FITC-dextran and 
FITC (Figure 1f), the sequestered GLU and calcium ions will be released into CSF during the AcDX 
degradation process. Based on the degradation rate of AcDX microspheres, GLU and calcium ions 
being released from microspheres is unlikely to be cytotoxic, especially at the acute and subacute 
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connections to the vascular system through the blood brain barrier would work to prevent the 
reestablishment of cytotoxic level of GLU and calcium ions.[43] Our finding implies that AcDX 
microspheres should be administrated as soon as possible following the initial injury to maximize their 
therapeutic efficacy. These results provide an interesting potential drug delivery application for our 
microspheres during the acute/subacute phase of SCI. 
This study demonstrates that the intrathecal administration of bare AcDX microspheres can protect 
neurons from GLU-induced excitotoxicity, and therefore, repair the injured spinal cord. The 
neuroprotective feature of AcDX microspheres is achieved by sequestering GLU and calcium ions in 
CSF, reducing the calcium ions influx into neurons and inhibiting the formation of ROS. Consequently, 
AcDX microspheres attenuate the expression of pro-apoptotic proteins (Calpain and Bax) and enhance 
the expression of anti-apoptotic protein (Bcl-2) both in vitro and in vivo. The intrathecal administration 
of AcDX microspheres immediately after traumatic injury leads to histological protection in spinal 
tissue and functional recovery in live animals. The administration of such microspheres or scaffolds 
may play an important role in the design of future strategies for the treatment of traumatic central 
nervous system injury, not limited to SCI. For example, benefiting from the protection effect of AcDX, 
the incorporation of therapeutic compounds into the AcDX-based drug delivery systems and scaffolds 
may bring synergistic outcome toward the SCI therapy and the treatment of other traumatic central 
nervous system injury. Follow-up studies will aim to load therapeutics into the AcDX microspheres to 
further improve the recovery of the injured spinal cord. In summary, our work opens an exciting 
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Spinal cord injury (SCI) is the result of an initial mechanical disruption in the spinal cord structures 
(primary insult), followed by a secondary event that collectively injures the intact neighboring tissue.[1] 
Worldwide, an estimated 2.5 million people are living with SCI, with more than 130 thousand new 
injuries reported annually.[2] Traumatic SCI is a debilitating injury that have a life-long impact on the 
injured person. The economic cost of SCI is estimated to be approximately 9.7 billion dollars annually 
in the United States.[3] Despite its significant societal and economic impacts, few clinical treatments 
exist for traumatic SCI, and they only have limited therapeutic efficacy.[4] Therefore, new therapeutic 
strategies with improved therapeutic efficacy have been actively pursued.[5] 
One of the promising approaches to treat traumatic SCI is using biomaterials. Several biodegradable 
polymers have been illustrated to support or promote axon regeneration in central nervous system. For 
example, the local administration of hydrogel composing of poloxamers (nonionic amphiphilic 
triblock copolymers) has been shown to slightly improve the functional motor recovery of injured 
spinal cord.[6] The self-assembled poly(ethylene glycol)−poly(D,L-lactic acid) block copolymer 
micelles repair the injured axonal membranes and reduce the calcium influx into axons, resulting in an 
improvement of locomotor function after traumatic SCI in adult rats.[7] Functional restoration of 
injured spinal cord has also been observed through the intravenously administration of ferulic acid 
modified glycol chitosan nanoparticles at 2 h post-injury.[8] Moreover, poly(lactic-co-glycolic acid),[9] 
poly(caprolactone fumarate)[10] and oligo[(polyethylene glycol) fumarate][11] have previously been 
shown to benefit the neuron repair.[12] 
Recently, a biodegradable water-insoluble polymer ‘acetalated-dextran’ (AcDX) was synthesized 
by modifying hydroxyl groups of water-soluble dextran with 2-methoxypropene.[13] Because of its 
high solubility in organic solvents, AcDX and its derivatives have been formulated into micro- and 
nano-particles for biomedical applications, such as immunotherapy[14] and myocardial infarction 
treatment.[15] The immunogenicity of subunit vaccines could be enhanced by encapsulating a protein 
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hepatocyte growth factor fragment were employed for the treatment of myocardial infarction.[15] The 
cardioprotective efficacy of payload was optimal when delivered over 3 days post-intramyocardial 
injection, yielding the largest arterioles and the fewest apoptotic cardiomyocytes bordering the 
infarct.[15a] 
After SCI, glutamate (GLU) floods out of injured spinal neurons, axons, and astrocytes, 
overexciting neighboring neurons.[16] The overexcited cells let in waves of calcium ions, which can 
trigger a series of destructive events, including production of highly reactive free radicals. These 
radicals can attack membranes and other cell organelles, and result in the neuronal death. These 
processes inevitably aggravate the injury of spinal cord. Hence, capturing GLU at the acute phase of 
injury may offer new treatment modalities for SCI therapy. In this study, we found out that the polymer 
AcDX itself can protect the injured spinal cord by reducing the level of GLU in cerebrospinal fluid 
(CSF) within hours after injection, and therefore, inhibit the GLU-induced excitotoxicity. Specifically, 
the intrathecally injected AcDX microspheres reduced the traumatic lesion volume, inhibited 
inflammatory response, protected the spinal cord neurons, and ultimately showed the improved 
locomotor function following traumatic SCI. 
The synthesis approach of AcDX is shown in Figure 1a.[13] In the presence of an acid catalyst (p-
toluenesulfonate), the modification of vicinal diols with 2-methoxypropene efficiently transformed the 
water soluble dextran into water insoluble AcDX.[14] Based on the 1H nuclear magnetic resonance 
(NMR; Figure 1b) spectrum of AcDX, the calculated conjugation ratio was approximately 80.4%, 
corresponding to 48 out of 60 glucose units in a dextran (MW 10,000 g/mol) modified by 2-
methoxypropene. Fourier transform infrared (FTIR; Figure 1c) spectra showed a clear intensity 
decrease of the O-H stretch at 3325 cm-1, which can be ascribed to the reaction of vicinal diols with 2-
methoxypropene. 
Microfluidic technology provides an easy-to-use approach for the preparation of monodisperse 
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focusing device (Figure 1d).[18] The device was composed of two types of capillaries for which the 
outer diameter (about 1.0 mm) of the cylindrical tapered capillary fitted the inner dimension (about 1.1 
mm) of the outer capillary. The inner oil fluid was an AcDX ethyl acetate solution (20 mg/mL) and 
the outer aqueous fluid contained amphiphilic Poloxamer 407 (10 mg/mL). The oil and aqueous fluids 
were simultaneously pumped into the microfluidic device in the opposite directions. This flow-
focusing geometry forced the inner oil fluid to breakdown, forming single O/W emulsion drops at the 
orifice of the inner capillary. All the collected droplets were solidified through the diffusion of ethyl 
acetate to the external aqueous phase. As shown in the scanning electron microscope (SEM) image 
(Figure 1e-i), the obtained AcDX microspheres are all spherical. Toward the fluorescein 
isothiocyanate (FITC)-loaded AcDX microspheres, the fluorescence intensity distribution within 
microspheres was uniform (Figure 1e-ii), indicating a solid structure of the obtained microspheres.[19] 
We can see from Figure 1e-iii, the average particle size of AcDX microspheres was approximately 
7.2 µm with a narrow size distribution (polydispersity index = 11.1%, defined as the ratio between the 
standard deviation and the mean diameter of particles multiplied by 100%). 
To monitor the degradation behavior of AcDX microspheres, the FITC-labelled AcDX was 
synthesized by modifying the vicinal diols of FITC-labelled dextran with 2-methoxypropene. At pH 
7.4, AcDX decomposed slowly through hydrolyzation of the acetals, regenerating the water-soluble 
FITC-dextran over a period of 50 days (Figure 1f).[15b] This degradation of AcDX microspheres is 
further reflected in the release profile of a model payload, FITC (Figure 1f). The release of FITC from 
AcDX microspheres was faster than that of FITC-dextran, which was only observed after 8 days of 
incubation. These two release profiles suggest that the payload only diffused out when the 
microspheres degraded, as opposed to passive diffusion through the intact microspheres. To 
corroborate these results, the degradation of AcDX microspheres was visualized using SEM. The 
morphology of the AcDX microspheres at day 1, 7, and 28 is shown in Figure 1g. The increased 
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at pH 7.4, most of the polymer matrix for AcDX microspheres was degraded. These SEM images 
correlate well with the observed FITC and FITC-dextran release profiles. 
We evaluated the cytocompatibility (activity of dehydrogenases) of AcDX microspheres with 
primary neurons (Figure 1h). No obvious cytotoxicity was observed for AcDX microspheres within 
the tested concentration range (0.1−4.0 mg/mL) and the selected incubation time (6−96 h). 
Interestingly, enhanced neuron activity was observed after incubating with AcDX microspheres for 24, 
48 and 72 h. After 24 h incubation, notable neuron viability enhancement was only observed for the 
highest concentration of AcDX microspheres (4.0 mg/mL). When the incubation time was extended 
to 48 h, remarkable cell viability increase was observed for AcDX microspheres with a concentration 
as low as 0.2 mg/mL. The cell viability enhancement effect for AcDX microspheres disappeared after 
increasing the incubation time to 96 h, which could be ascribed to the accumulation of by-products of 
cellular metabolism inside the medium. The cytocompatibility test suggests the neuroprotective effect 







































































Figure 1. Preparation and characterization of AcDX microspheres and their neuronal 
compatibility. (a-c) Single-step synthesis of AcDX (a), and its NMR (b) and FTIR (c) spectra. (d) A 
schematic diagram of AcDX microspheres prepared by droplet microfluidics. (e) SEM (i) and confocal 
fluorescence microscopy (ii) images of the obtained AcDX microspheres, and their size distribution 
(iii). (f) Dissolution of FITC-dextran and FITC from AcDX microspheres in 1 × phosphate-buffered 
saline (1 × PBS, pH 7.4) at 37 °C (n = 3). (g) SEM images of AcDX microspheres after 1, 7 and 28 
days of incubation in PBS (pH 7.4) at 37 °C. (h) The effect of AcDX microspheres (0.1-4.0 mg/mL) 
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microspheres were compared with that of the PBS group. Data present as mean ± s.d.; the levels of 
significance were set at probabilities of *P < 0.05 and **P < 0.01. 
 
To verify the neuroprotective effect of AcDX microspheres, we performed a functional motor 
assessment and histological injury study in Sprague-Dawley rats undergoing a weight-drop injury of 
the thoracic spinal cord (T10; Figure 2a). Regarding all the in vivo test, AcDX microspheres (60 µg/µL, 
10 µL in total) were intrathecally administrated within 5 min post-injury. Because the cerebrospinal 
fluid volume in rat brain is approximately 580 μL,[20] the theoretical total volume would be 
approximately 590 μL after the administration of AcDX microspheres. Therefore, the final AcDX 
concentration (600 µg in 590 µL) achieved about 1 mg/mL, which was proved to be effective in neuron 
viability enhancement (Figure 1h). The vehicle PBS served as the control (SCI group). The 
degradation rate of AcDX is primarily controlled by the pH value of the incubation medium.[21] After 
intrathecally administration, the AcDX microspheres were dispersed in CSF. In general, CSF is clear, 
colorless, nearly acellular, and has a low protein concentration.[22] Since the component, especially the 
pH value, of CSF is similar to the in vitro incubation medium, the in vivo degradation rate of AcDX is 
also expected to be close to that observed in vitro. Instead of breaking into smaller pieces, AcDX 
microspheres presented an “outside-in” pattern of degradation (Figure 1g). Their degradation pattern 
indicates that AcDX microspheres would remain inside the CSF before complete degradation. 
After traumatic SCI, the motor behavior was assessed by the 21-point Basso, Beattie, and Bresnahan 
(BBB) locomotor rating scale in open-field (Figure 2b). The complete hindlimb paralysis (BBB score 
= 0) was observed for both SCI and AcDX groups at day 1 post-injury. At day 7 post-injury, the AcDX 
group showed extensive movement of two joints (BBB score = 3.0 ± 0.8), which is significantly (P = 
0.040) higher than the locomotor performance of SCI group (BBB score = 1.8 ± 0.5) with the extensive 
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maintained over the remainder of the motor assessment study. At day 28 post-injury, the plantar 
support of the paw with weight bearing only in the support stage was observed for the AcDX group 
with a score of 8.5 ± 1.3 on the BBB scale, whereas non-treated rats were approximately 2 points lower 
(P < 0.05). Overall, AcDX significantly improved the recovery of hindlimb motor function. In terms 
of the BBB score for the SCI group, it increased from 0 at day 1 post-injury to 6.5 ± 0.6 at day 28 after 
SCI, indicating a certain degree of spontaneous motor function recovery. This spontaneous locomotor 
function recovery was also included in the result of the AcDX group. 
As shown by the gross morphology of the injured spinal cords, the traumatic lesion area (brown 
colored region) on the spinal cord was visible (Figure 2c). After treatment with AcDX microspheres, 
the lesion area was notably smaller than that of the SCI only group. A prominent pathological feature 
of SCI is the development of a fluid-filled cystic cavity that is bordered by reactive astrocytes.[23] The 
traumatic lesion cavity was identified by loss of cells using Nissl staining to study whether AcDX 
microspheres could reduce the lesion volume. Four weeks after injury, dramatic tissue loss on the 
injured spinal cord was observed (Figure 2c). The administration of AcDX microspheres caused a 
reduction in post-traumatic spinal cord tissue loss. Lesion volume was assessed by the Nissl-stained 
spinal cord sections, which sampled serially in the longitudinal plane with an interval of about 200 µm 
for each layer. As demonstrated in Figure 2c, the administration of AcDX microspheres significantly 
decreased (P = 0.002) the lesion volume (2.9 ± 0.9 mm3) compared to the SCI control group (8.6 ± 1.1 
mm3). 
To further understand the anatomical basis of the observed locomotor recovery, we examined the 
density or status of astrocytes, microglia, neurons, and axons. These cells play crucial roles in the 
spinal cord damage and repair. The cellular hypertrophy and increases in glial fibrillary acidic protein 
(GFAP) are hallmarks of astrocyte reactivity after SCI.[24] The injured spinal cord is also featured with 
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The reactive astrocytes and microglia were visualized using GFAP and CD68 immunofluorescence 
antibodies, respectively. 
Regarding the non-treatment (SCI) group, the region in proximity to the lesion area was 
characterized by hypertrophic astrocytes with multiple GFAP+ processes for both day 1 (Figures 2d 
and 2f) and 28 (Figures S1 and S2) post-injury, matching the appearance of SCI-associated local 
astrogliosis.[26] The GFAP immunoreactivity near the injury site was higher than that located further 
(> 10 mm) from the traumatic lesion area (Figure 2h). Specifically, we observed 29.4 ± 9.9% and 36.0 
± 17.8% GFAP intensity increase at 1 and 28 days post-injury, respectively, adjacent to the lesion area 
for SCI group. In the AcDX group, peritraumatic astrocytes were morphologically indistinguishable 
from astrocytes located distal to the injury site for both day 1 (Figures 2e and g) and 28 (Figure S3 
and S4) post-injury. At day 1 post-injury, the GFAP intensity of peritraumatic astrocytes was 15.0 ± 
2.7% higher than that located further from the traumatic lesion area. This effect was continuous, 
because the peritraumatic GFAP intensity was only 8.1 ± 6.7% higher than that located further from 
the traumatic lesion area at day 28 post-injury. Hence, AcDX treatment significantly (P < 0.05, for 
both day 1 and 28 post-injury) and persistently inhibited the astrocytic response, as well as reduced 
the severity of initial reactive gliosis after SCI. 
To evaluate the effect of AcDX treatment on microglial activation following SCI, we also quantified 
the number of activated microglial cells adjacent to the injury site and in the traumatic lesion area by 
immunodetection of CD68+ microglia (Figures 2d, 2e, S1 and S3). At both day 1 and 28 post-injury, 
we did not observe any notable difference (Figure S5) on the number of CD68+ cells in the 
peritraumatic area between the SCI only and AcDX groups. In contrast, a significant reduction in the 
number of CD68+ microglia in the traumatic lesion area was observed with AcDX treatment compared 
to rats injected with only PBS at both day 1 (P = 0.004) and 28 (P < 0.001) post-injury (Figure 2i). In 
the lesion area, the density of microglia was 931 ± 75 per square millimeter at day 1 post-injury. After 
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square millimeter. Regarding the AcDX group, the CD68+ microglia density only slightly increased 
from 727 ± 51 to 840 ± 219 per square millimeter within 28 days. At day 28 post-injury, a reduction 
in the number of CD68+ microglia by about 65% in the traumatic lesion area was observed with AcDX 
treatment (P < 0.001) compared to rats injected with only PBS. Besides astrocytic response inhibition, 
AcDX efficiently restrained the inflammatory response associated to the microglia activation.[27] 
Neurofilaments are cell type specific proteins in central nerve system, and qualified as potential 
surrogate markers of damage to neuron and axon.[28] The immunostaining analysis of 200 kDa subunit 
of neurofilament (NF200), which contributes to anomalous electrophoretic mobility, has been 
employed to evaluate the neuron and axon damage.[29] In the control (SCI) group (Figures 2f and S2), 
the NF200 immunoreactivity near the injury site was lower, 32.3 ± 1.7% and 29.8 ± 16.2% decrease 
at day 1 and 28 post-injury, than that located distant from the traumatic lesion area (Figure 2j). 
Regarding the AcDX group, the NF200 intensity of peritraumatic area was 19.2 ± 1.9% lower than 
that located further from the traumatic lesion area at day 1 post-injury (Figures 2g and 2j). When the 
time extended to 28 days post-injury, the NF200 intensity of peritraumatic area was only 3.9 ± 5.5% 
lower than that located further from the traumatic lesion area for the AcDX group (Figures S4 and 2j). 
In comparison with the SCI only group, a significant increase (P < 0.05 for both 1 and 28 days post-
injury) in NF200 labeling adjacent to the injury site was observed for AcDX treated group, suggesting 
the continuous neuronal protection effect of AcDX microspheres. 
Western blot analysis was used to further validate the immunofluorescence analysis (Figure 2k). A 
semi-quantitative comparison of Western blot images showed that the GFAP expression in the AcDX 
group was significantly (P = 0.048) reduced as compared to the SCI only group (Figure 2l). Besides 
GFAP, the AcDX treatment also significantly (P = 0.014) reduced the CD68 expression (activation of 
microglia) at day 1 post-injury. A comparison of the NF200 expression demonstrated that AcDX 
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results is highly consistent with the immunohistochemical studies, suggesting that AcDX can inhibit 
the reactivity of injury-related proteins and protect the injured neurons. 
These immunohistochemistry results collectively demonstrate that AcDX microspheres not only 
suppressed the astrogliosis and inflammation, but also protected neurons, making AcDX a promising 
biomaterial for SCI treatment. The neuroprotective effect in the spinal cord tissue contributed to the 
rapid recovery of walking motion as early as 1 week after administration. The histological data 
corroborated the functional recovery results, showing that AcDX microspheres can enhance the 
recovery of injured spinal cord. However, the mechanism of neuronal protection by AcDX 
microsphere is unclear. In the following content, we further studied the possible mechanism for the 
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Figure 2. AcDX microspheres protect the traumatically injured spinal cord. (a) Schematic 
diagram of experimental design. AcDX microspheres were intrathecally injected within 5 min after 
weight drop at the T10 level. (b) The rats were functionally graded up to 28 days post-injury using the 
BBB grading scale (n = 5 animals per group). (c) Spinal cord at day 28 post-injury: (i) gross 
morphology, (ii) representative Nissl stained sagittal sections, and (iii) the lesion volumes (n = 3 
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and CD68 (in red) in the spinal cord tissues of SCI (d) and AcDX (e) groups at day 1 post-injury. The 
boundary of cavity is indicated by the dashed lines. Right two columns are the enlarged images 
corresponding to the distant (> 10 mm) field to the lesion (upper row), and the lesion area (bottom 
row). The nuclei of all cells were stained with DAPI (in blue). (f and g) Representative 
immunohistochemical staining images of GFAP (in green) and NF200 (in red) in the injured spinal 
cord tissues of SCI (f) and AcDX (g) groups at day 1 post-injury. The dashed lines indicate the 
boundary of cavity. (h-j) Semi-quantification of GFAP intensity increase (h; n ≥ 5 animals per group), 
the number of CD68+ microglia in the traumatic lesion area (i; n ≥ 4 animals per group), and NF200 
intensity decrease (j; n ≥ 4 animals per group). (k) Representative Western blots of NF200, CD68 and 
GFAP in lesion extracts at day 1 post-trauma. (l) Semi-quantification of relative expression level of 
NF200, CD68 and GFAP, normalized to GAPDH (n = 3 animals per group). Data present as mean ± 
s.d.; the levels of significance were set at probabilities of *P < 0.05, **P < 0.01, and ***P < 0.001. 
 
Excitotoxicity is one of the most important pathological and neurochemical changes after SCI. 
Specifically, neurons are under the excessive stimulation by neurotransmitter GLU;[30] the high GLU 
concentration around the synaptic cleft induces the neuronal cell death. Neuron apoptosis contributes 
to the neuronal cell death and to the neurological dysfunction, induced by traumatic insults to the rat 
spinal cord.[31] We studied the neuronal apoptosis by propidium iodide (PI)/Hoechst 33342 (HC) 
staining (Figure 3a). The high intensity of PI indicates the cell death. HC staining was performed to 
visualize the nuclear morphology of neurons and to distinguish those apoptotic ones. The control 
neurons exhibited uniformly dispersed chromatin and intact cell membrane (PI-negative). The high 
magnification of neurons for each group is shown in Figure S6. After the administration of GLU, 
neurons exhibited typical characteristics of apoptosis, such as the condensation of chromatin, the 
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effect of AcDX microspheres on the GLU-induced excitotoxicity model. Three concentrations of 
AcDX microspheres, 0.25 mg/mL (AcDXL), 1.0 mg/mL (AcDXM) and 4.0 mg/mL (AcDXH), were 
selected for the following in vitro tests. Independent on the AcDX concentrations tested, the number 
of neurons with nuclear condensation and fragmentation decreased after AcDX microsphere treatment. 
We further investigated the protection mode of AcDX microspheres by staining primary neurons 
with paired FITC-labelled annexin V (FAV; in green) and PI (in red), and then examined it by flow 
cytometry (Figure 3b). In terms of early apoptotic cells, there was a prolonged maintenance of 
membrane integrity and an externalization of phosphatidylserine to which the FAV could specifically 
bind. Live cells were negative for both stains, whereas early apoptotic cells were characterized by a 
high FAV signal in the absence of PI staining. The viability of neurons decreased to about 50% (Figure 
3c) after GLU-induced excitotoxicity, about one third of neurons had lost membrane integrity (PI-
positive; Figure 3d), and approximately 13% neurons were at the early apoptotic stage (FAV-positive 
and PI-negative; Figure 3e). Under the protection of AcDX microspheres, the viability of neurons was 
significantly improved (P < 0.01) for all three concentrations tested. As expected, the fraction of PI- 
and FAV-positive neurons significantly (P < 0.01) decreased when neurons were incubated with 
AcDX microspheres. The strongest protection effect was observed for the AcDXM group. The flow 
cytometry measurements were consistent with the fluorescence image analysis; both results indicated 
that AcDX microspheres can protect primary neurons from GLU-induced excitotoxicity. 
Next, we analyzed the expression level of pro-apoptotic proteins (Calpain and Bax), anti-apoptotic 
protein (Bcl-2), and the apoptotic symbol caspases enzymes in primary neurons to preliminarily 
understand the mechanism of anti-apoptosis effect of AcDX microspheres (Figure 3f).[32] Among the 
caspases discovered, caspase-3 is an executioner of apoptosis, cleaving several essential downstream 
substrates.[33] Moreover, the activation of caspase-9, an important initiator of apoptosis, has been 
implicated in SCI.[34] The semi-quantitative analysis of Western blot images is presented in Figure 3g. 
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(P < 0.001), Caspase-9 (P = 0.011) and Caspase-3 (P = 0.003), and Bax (P = 0.004) were observed in 
primary neurons, when compared to the PBS group. In contrast, the expression level of Bcl-2 notably 
decreased (P < 0.001) when GLU was added. After the administration of AcDX microspheres, the 
Western blot analyses revealed lower levels of Calpain and Caspase-9 and Caspase-3 than those of 
GLU group, whereas the expression of Bcl-2 improved. In terms of Bax, no significant difference was 
observed for the AcDXL and AcDXM groups when compared to the GLU group. The expression level 
of Bax for AcDXH was even significantly (P = 0.002) higher than that from the GLU group. The 
neuronal protection effect of AcDX microspheres can attributed to the attenuation of pro-apoptotic 
proteins (Calpain, Caspase-9 and Caspase-3) and the enhanced expression of anti-apoptotic protein 
(Bcl-2). Furthermore, the ratio of Bcl-2 to Bax is known as a key determinant of neuronal commitment 
to apoptosis.[35] Bcl-2/Bax increased for AcDX microspheres compared with GLU group, indicating 
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Figure 3. AcDX microspheres alleviate the GLU-induced neuronal apoptosis in vitro. For in vitro 
tests, the neurons were firstly incubated with microspheres for 15 min, followed by the administration 
of GLU (100 μM) for all the groups, except for the PBS one. (a) Representative fluorescence images 
of propidium iodide (PI, in red; marker of dead cells) and Hoechst 33342 (HC, in blue; nuclear marker 
for both survival and apoptotic cells) stained neurons incubated with AcDX microspheres after GLU-
induced excitotoxicity. (b) Examples of scatter plots for neurons incubated with AcDX microspheres 
after GLU-induced excitotoxicity by PI/FAV double labeling. (c−e) Quantitative results of live (c), 
and PI- (d) and FAV-positive (e) neurons with and without the treatment by AcDX microspheres (n = 
3). (f) Representative Western blot analysis of apoptosis indicated proteins in neurons incubated with 
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level of apoptosis indicated proteins in primary neurons, normalized to GAPDH (n = 3). The AcDX 
microspheres were compared with the groups of PBS (*) and GLU (#). Data present as mean ± s.d.; the 
levels of significance were set at probabilities of *, #P < 0.05, **, ##P < 0.01, and ***, ###P < 0.001. 
 
We assessed the extent of cell apoptosis in the peritraumatic zone of spinal cord by the terminal 
deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay. The selected TUENL 
assay time point was 1 day post-injury, when a burst of neuronal and glial apoptosis in gray and white 
matter at the lesion site was observed.[31] The sagittal sections of the spinal cords treated with PBS and 
AcDX microspheres are presented in Figure 4a. High magnification of sagittal sections showed a clear 
cellular alteration of typical apoptosis, green colored and indicated by white arrows (Figure S7). On 
day 1 post-injury, the numbers of TUNEL-positive (apoptotic) cells for AcDX group was dramatically 
smaller (P = 0.006) than those treated with PBS (Figure 4b). The in vivo TUNEL assay confirmed 
that AcDX microspheres can effectively inhibit the cell apoptosis in the injured spinal cord, and these 
results are consistent with the in vitro tests. 
The expression of apoptosis associated markers in the traumatic injured spinal cord was also 
evaluated by Western blot analysis (Figure 4c). The semi-quantitative comparison of Western blot 
images is shown in Figure 4d. The local delivery of AcDX microspheres prominently improved Bcl-
2 (P = 0.022) expression and significantly reduced the expression level of Calpain (P < 0.001), 
Caspase-9 (P < 0.001), Caspase-3 (P = 0.012) and Bax (P = 0.002), as compared to the SCI only group. 
AcDX microspheres attenuated the pro-apoptotic proteins (Calpain, Caspase-9 and -3, and Bax) 
expression, and enhanced the expression of anti-apoptotic protein (Bcl-2), which corroborates the in 
vitro tests (Figures 3f and 3g). In comparison to the SCI group, the higher Bcl-2/Bax ratio for the 
AcDX group indicates that the mitochondria-mediated cell death pathway in injured spinal cord can 
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Figure 4. AcDX microspheres protect the injured neurons from apoptosis in vivo. (a) 
Representative images of TUNEL-positive apoptotic cells (in green) in sagittal spinal cord sections at 
day 1 post-trauma. The nuclei of all cells were stained with DAPI (in blue). (b) Comparison of the 
number of TUNEL-positive cells with and without AcDX microspheres treatment (n = 5 animals per 
group). (c) Representative Western blots of apoptosis indicated proteins in lesion extracts at day 1 
post-trauma. (d) Semi-quantification of relative expression level of apoptosis indicated proteins, 
normalized to GAPDH. In terms of in vivo tests, the vehicle PBS served as the control (SCI group; n 
= 3 animals per group). Data present as mean ± s.d.; the levels of significance were set at probabilities 
of *P < 0.05, **P < 0.01, and ***P < 0.01. 
 
In general, the pathologically high level of GLU can cause excitotoxicity by sustained calcium ion 
influx through GLU receptor channels, which is a common pathway of neuronal apoptosis.[36] We 
employed a calcium indicator, Fluo-4 AM ester, to monitor the intracellular calcium transients before 
and after the AcDX microsphere treatment.[37] Calcium influx by microscopy live imaging was 
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change of Fluo-4 intensity in comparison to F0. The time course of the Fluo-4 signals (∆F/F0) as a 
function of time has been presented in Figure 5a. The GLU stimulation increased the peak intensity 
of Fluo-4 by approximately 5-fold, and peaked after approximately 2 min GLU stimulation. The 
incubation with ACDX microspheres before GLU stimulation effectively reduced the peak intensity 
of Fluo-4 for neurons. Specifically, the intracellular peak level of Fluo-4 reduced by approximately 
30% (P = 0.041), 41% (P = 0.001) and 45% (P < 0.001) for AcDXL, AcDXM and AcDXH groups, 
respectively, in comparison with the GLU group (Figure 5b). After 5 min GLU stimulation, the Fluo-
4 intensity difference was only observed between GLU and AcDXM (P = 0.019). Figure 5c shows the 
representative Fluo-4 fluorescence images of GLU-stimulated neurons incubated with different 
concentrations of AcDX microspheres. Overall, the neuronal protection effect of AcDX microspheres 
could be ascribed to the reduced calcium influx into neurons, which has also been observed for the 
poly(ethylene glycol)−poly(D,L-lactic acid) block copolymer.[7] 
The high calcium ion loads increase the risk for mitochondrial damage, triggering the mitochondrial 
production of reactive oxygen species (ROS).[38] Hence, we monitored the intracellular ROS level to 
further corroborate the neuronal protection effect of AcDX microspheres.[39] The cell-permeant 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA) was used as an indicator to detect the intracellular 
level of ROS in injured neurons. Oxidation of H2DCFDA, forming highly fluorescent 2',7'-
dichlorofluorescein (DCF), as determined using confocal microscopy was barely detectable in 
uninjured neurons (Figure 5d). The intensity of DCF fluorescence in GLU incubated neurons was 
markedly increased. Meanwhile, the administration of AcDX microspheres reduced the level of DCF 
fluorescence. The intensity changes of intracellular DCF fluorescence in different groups were 
confirmed by flow cytometry analysis (Figures 5e and 5f). Based on the MFI values, only the 
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Figure 5. AcDX microspheres reduce the GLU-induced calcium ion influx and production of 
reactive oxygen species. (a) The time course of the Fluo-4 signals (∆F/F0) as a function of time, with 
F0 being the baseline Fluo-4 fluorescence and ∆F the change of Fluo-4 fluorescence in comparison to 
F0. (b) Quantification of regions of interest demonstrating the effect of AcDX microspheres on 
reducing the fluorescence over time in response to GLU (n = 11). (c) Representative calcium images 
of neurons incubated with AcDX microspheres before (0 min) and after (2 min) GLU stimulation. (d-
f) Representative ROS imaging (d), flow cytometry histograms (e), and the corresponding MFI (f; n = 
3) of injured neurons incubated with AcDX microspheres. The MFI values were normalized to that of 
the PBS group. Data present as mean ± s.d.; the groups treated with AcDX microspheres were 
compared with the GLU group (*); the levels of significance were set at probabilities of *P < 0.05, **P 
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Lohmann et al.[40] synthesized glycosaminoglycan-based hydrogels, which can capture 
inflammatory chemokines to accelerate the wound healing. Inspiring by this inflammatory chemokine 
capture, we hypothesize that AcDX microspheres can alleviate the GLU-induced excitotoxicity 
through the physical adsorption of GLU. To verify this hypothesis, we evaluated the adsorption 
kinetics of GLU to AcDX microspheres, which was determined by incubation with 50 µM of GLU in 
artificial CSF (aCSF) As illustrated in Figure 6a, the more AcDX microsphere we added, the more 
GLU was adsorbed. For example, the adsorption of GLU up to about 6% was achieved, when the 
concentration of AcDX microspheres was 1 mg/mL. Moreover, the adsorption capacity of AcDXM 
and AcDXH for GLU was analyzed by incubating with a variety concentration of GLU in aCSF (25, 
50 and 100 µM) for 30 min (Figure 6b). A linear correlation of the amounts of deployed and adsorbed 
GLU was found for both AcDXM and AcDXH. By increasing the GLU concentration from 25 to 100 
µM, the percentage of GLU sequestered by AcDX microspheres decreased from 8% to 4% for AcDXM, 
and reduced from 22% to 10% for AcDXH. 
We further verified the GLU capture capability of AcDX microspheres in vivo (Figure 6c). Detailed 
CSF sampling (100-150 μL) has been illustrated in Video S1. The GLU content in CSF was analyzed 
by an ultra-performance liquid chromatography and tandem mass spectrometry; a representative 
chromatogram of GLU in the CSF sample from the SCI only group at day 2 post-injury has been 
presented in Figure S8. Before injury, the GLU concentration in CSF is approximately 4 µM (t = day 
0). For both SCI and AcDX groups, the GLU concentration in CSF continually increased until day 2 
post-injury, and then decreased to a level (approximately 2 and 1 µM for SCI and AcDX, respectively) 
even lower than the normal GLU concentration (4 µM). Until day 4 post-injury, the GLU concentration 
for AcDX group was always significantly lower than that for the SCI only group. Specifically, after 
the administration of AcDX microspheres, the GLU concentration decreased from approximately 18 
to 8 µM (P < 0.05) at 8 h post-injury, from approximately 77 to 58 µM (P < 0.001) at day 2 post-injury, 
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under the curve (AUC) of GLU concentrations in CSF (d). The AUC of GLU for the group treated by 
AcDX microspheres was also significantly (P < 0.01) lower than that of the SCI only group. Based on 
both in vitro and in vivo GLU adsorption results, we can conclude that our AcDX microspheres can 
protect neurons from excitotoxicity by sequestering the GLU in CSF. 
The overload of calcium ions is one of the most important features for the GLU-induced 
excitotoxicity, hence we also evaluated the adsorption capability of AcDX microspheres toward 
calcium ions. Surprisingly, the AcDX microspheres can also scavenge the calcium ions in aCSF 
(Figure 6e). This calcium ion scavenging capability of AcDXM and AcDXH was also confirmed by 
the relation between the deployed and adsorbed calcium ions (Figure 6f). Like the sequestering effect 
toward GLU in CSF, the administrated AcDX microspheres also reduced the intensity of the calcium 
ions in CSF (Figure 6g). In comparison to the SCI group, significantly lower calcium ion 
concentrations were observed at 8 h (P < 0.05), and day 1 (P < 0.01), 2 (P < 0.001) and 4 (P < 0.001) 
post-injury; the AUC of calcium ions for the group treated by AcDX microspheres was also 
significantly reduced (P < 0.001; Figure 6h). Therefore, the neuronal protection effect of AcDX 
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Figure 6. AcDX microspheres alleviate GLU-induced excitotoxicity by sequestering GLU and 
calcium ions. (a) The adsorption of GLU (50 µM) by AcDX microspheres in aCSF in terms of the 
microsphere concentrations (n = 6). (b) The impact of GLU concentrations on the adsorption of GLU 
by AcDX microspheres in aCSF (n = 6). (c and d) The effect of AcDX microspheres on the 
concentrations of GLU in the CSF as a function of time (c; n ≥ 3 animals per time point) and the 
corresponding area under curve (d; n = 3). (e) The adsorption of calcium ions (0.5 mM) by AcDX 
microspheres in aCSF in terms of the microsphere concentrations (n = 6). (f) The impact of calcium 
ion concentrations on the adsorption of calcium ions by AcDX microspheres in aCSF (n = 6). (g and 
h) The effect of AcDX microspheres on the concentrations of calcium ions in the CSF as a function of 
time (g; n ≥ 3 animals per time point) and the corresponding area under curve (h; n = 3). Data present 
as mean ± s.d.; the groups treated with AcDX microspheres were compared with the SCI only group 
(*); the levels of significance were set at probabilities of *P < 0.05, **P < 0.01 and ***P < 0.001. 
 
GLU and calcium ions play a key role in excitotoxicity, which leads to neuronal cell apoptosis.[41] 
AcDX microspheres show the capability of buffering out excess GLU and calcium ions. Benefiting 
from the fast sequestering of GLU and calcium ions by AcDX microsphere, significantly lower level 
of GLU and calcium ions in CSF has been achieved at the first evaluation time point (8 h post-injury). 
By reducing the magnitude of the initial increase of extracellular GLU and calcium ions during the 
acute (2-48 h post-injury) and subacute (2-14 days post-injury) phases of SCI,[42] AcDX microspheres 
successfully attenuate the degree of excitotoxic secondary neuron damage. Like FITC-dextran and 
FITC (Figure 1f), the sequestered GLU and calcium ions will be released into CSF during the AcDX 
degradation process. Based on the degradation rate of AcDX microspheres, GLU and calcium ions 
being released from microspheres is unlikely to be cytotoxic, especially at the acute and subacute 
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connections to the vascular system through the blood brain barrier would work to prevent the 
reestablishment of cytotoxic level of GLU and calcium ions.[43] Our finding implies that AcDX 
microspheres should be administrated as soon as possible following the initial injury to maximize their 
therapeutic efficacy. These results provide an interesting potential drug delivery application for our 
microspheres during the acute/subacute phase of SCI. 
This study demonstrates that the intrathecal administration of bare AcDX microspheres can protect 
neurons from GLU-induced excitotoxicity, and therefore, repair the injured spinal cord. The 
neuroprotective feature of AcDX microspheres is achieved by sequestering GLU and calcium ions in 
CSF, reducing the calcium ions influx into neurons and inhibiting the formation of ROS. Consequently, 
AcDX microspheres attenuate the expression of pro-apoptotic proteins (Calpain and Bax) and enhance 
the expression of anti-apoptotic protein (Bcl-2) both in vitro and in vivo. The intrathecal administration 
of AcDX microspheres immediately after traumatic injury leads to histological protection in spinal 
tissue and functional recovery in live animals. The administration of such microspheres or scaffolds 
may play an important role in the design of future strategies for the treatment of traumatic central 
nervous system injury, not limited to SCI. For example, benefiting from the protection effect of AcDX, 
the incorporation of therapeutic compounds into the AcDX-based drug delivery systems and scaffolds 
may bring synergistic outcome toward the SCI therapy and the treatment of other traumatic central 
nervous system injury. Follow-up studies will aim to load therapeutics into the AcDX microspheres to 
further improve the recovery of the injured spinal cord. In summary, our work opens an exciting 




Experimental section and supporting figures are enclosed in Supporting Information, which is 
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